Download Sample
Add to CartNeurological Biomarkers Market
By Type;
Genomic, Proteomic, Metabolomic, Imaging and OthersBy Application;
Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder and OthersBy End Use;
Research Organizations, Pharma & Biotech Companies and Clinical DiagnosticsBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)Neurological Biomarkers Market Overview
Neurological Biomarkers Market (USD Million)
Neurological Biomarkers Market was valued at USD 9,881.11 million in the year 2024. The size of this market is expected to increase to USD 21,437.69 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 11.7%.
Neurological Biomarkers Market
*Market size in USD million
CAGR 11.7 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 11.7 % |
| Market Size (2024) | USD 9,881.11 Million |
| Market Size (2031) | USD 21,437.69 Million |
| Market Concentration | Low |
| Report Pages | 380 |
Major Players
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Bio-Rad Laboratories, Inc.
- Myriad Genetics, Inc.
- Merck KGaA
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers AG
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Neurological Biomarkers Market
Fragmented - Highly competitive market without dominant players
The Neurological Biomarkers Market is witnessing substantial growth, driven by the rising demand for early diagnosis techniques, personalized medicine solutions, and advanced neurodegenerative disease management. With increasing adoption of biomarker-based diagnostics, genomic profiling, and targeted therapies, the market has recorded nearly 25% growth in overall utilization. Manufacturers and research institutes are focusing on innovative assay development and precision-driven diagnostic platforms to improve clinical outcomes.
Technological Advancements Driving Innovation
Rapid progress in molecular diagnostics, AI-integrated analytics, and next-generation sequencing is reshaping the neurological biomarker landscape. Around 29% of healthcare organizations are adopting digital biomarker platforms, blood-based assays, and CSF biomarker testing solutions to enhance diagnostic accuracy. Integration of machine learning algorithms and cloud-based analytics is accelerating biomarker discovery and supporting improved therapeutic decision-making.
Rising Applications Across Healthcare
The demand for neurological biomarkers is growing across hospitals, clinical laboratories, research institutions, pharmaceutical companies, and diagnostic centers, contributing to nearly 34% of overall adoption. Healthcare providers are leveraging multi-omics platforms, neuroimaging biomarker integration, and point-of-care testing technologies to improve patient management. The growing focus on neurodegenerative disease detection and personalized therapy optimization is driving new opportunities in the market.
Future Growth Prospects
The Neurological Biomarkers Market is expected to expand rapidly as companies invest in AI-powered biomarker discovery, liquid biopsy techniques, and next-generation diagnostic solutions. Over 42% of research organizations are projected to adopt multi-biomarker panels and digital diagnostic platforms for improved disease prediction and patient monitoring. Ongoing innovations and increasing integration of personalized diagnostics are set to unlock substantial growth potential in the coming years.
Neurological Biomarkers Market Key Takeaways
-
Growing adoption of neurological biomarkers is driven by their ability to enable early detection of conditions like Alzheimer’s, Parkinson’s and multiple sclerosis, improving treatment outcomes significantly.
-
Advancements in technology, such as high-sensitivity assays and imaging techniques, are enhancing the precision of biomarker detection and fueling their integration in clinical diagnostics.
-
Biopharmaceutical companies are increasingly investing in biomarker-based drug development, with nearly 60% of ongoing neurological trials incorporating biomarkers for validation and monitoring.
-
Academic and clinical research institutions are accelerating biomarker studies, with collaborations contributing to improved understanding of disease progression and patient stratification.
-
North America leads due to strong R&D funding and established healthcare infrastructure, while Europe and Asia-Pacific are rapidly expanding their footprint with rising neurological disease prevalence.
-
Regulatory support is strengthening biomarker validation, with agencies encouraging their use in clinical trials to streamline drug approvals and enhance patient safety.
-
Rising demand for non-invasive testing methods, including blood-based and imaging biomarkers, is gaining traction, with adoption rates climbing over 40% in recent years.
Neurological Biomarkers Market Recent Developments
- In July 2023, Quanterix Corporation launched LucentAD, a groundbreaking blood test designed to advance Alzheimer’s detection. By using specific biomarkers, it enables healthcare providers to identify early signs of the disease with greater precision. This innovation marks a significant step toward earlier diagnosis and improved patient management in neurodegenerative care.
- In April 2024, the Bill & Melinda Gates Foundation awarded a USD 1.5 million grant to Owlstone Medical. The funding supports the advancement of breath-based diagnostics, focusing on detecting critical breath biomarkers that can aid in the identification of tuberculosis and HIV, enhancing early disease detection and healthcare outcomes.
Segment Analysis
The comprehensive report on the Global Neurological Biomarkers Market delves deeply into various market segments, offering an extensive analysis that includes revenue analysis for both historic and forecast periods. Each market segment is meticulously examined, providing a detailed overview of key data points relevant to the segment's performance. The analysis is substantiated with robust data points, ensuring accuracy and reliability in assessing market trends and patterns. By incorporating historical data alongside future projections, the report offers a comprehensive understanding of market dynamics and growth trajectories across different segments.
The insights derived from data analysis enrich the report's value by uncovering significant trends, patterns, and market drivers within each segment. These insights are crucial in identifying growth opportunities, market challenges, and potential areas for innovation and investment. By leveraging data-driven analysis, the report provides actionable intelligence to stakeholders, enabling informed decision-making and strategic planning. Moreover, the report highlights key factors influencing market growth, such as technological advancements, regulatory landscapes, competitive dynamics, and shifting consumer preferences.
The in-depth analysis of revenue trends and forecasts for each market segment enhances the report's credibility and usefulness to industry professionals, investors, and policymakers. By presenting a clear picture of market performance and growth potential, the report facilitates a nuanced understanding of market opportunities and risks. Additionally, the incorporation of data-driven insights adds depth and context to market assessments, offering valuable perspectives on market dynamics and competitive landscapes. Overall, the report serves as a valuable resource for navigating the complexities of the Global Neurological Biomarkers Market and making informed decisions in a rapidly evolving healthcare landscape.
Global Neurological Biomarkers Segment Analysis
In this report, the Global Neurological Biomarkers Market has been segmented by Product Type, Indication, Imaging Techniques, , End User, and Geography.
Global Neurological Biomarkers Market, Segmentation by Product Type
The Global Neurological Biomarkers Market has been segmented by Product Type into Genomics Biomarker, Proteomics Biomarker, Imaging Biomarker, Metabolomics Biomarker, and Others.
The segmentation of the Global Neurological Biomarkers Market by product type reflects the diverse methodologies and approaches used in biomarker discovery, validation, and application. Genomics Biomarkers stand out as a pivotal segment, focusing on genetic variations, mutations, and gene expression patterns associated with neurological disorders. Genomic biomarkers aid in identifying disease risk, predicting treatment responses, and guiding personalized medicine interventions based on an individual's genetic profile.
Proteomics Biomarkers represent another critical segment, encompassing the study of proteins and their alterations in neurological diseases. Proteomic biomarkers offer insights into disease mechanisms, protein pathways, and biomolecular signatures indicative of disease states. These biomarkers play a crucial role in diagnostic assays, therapeutic target identification, and monitoring treatment responses, contributing to precision medicine advancements in neurology.
Imaging Biomarkers, Metabolomics Biomarkers, and other categories also contribute significantly to the Global Neurological Biomarkers Market. Imaging biomarkers utilize various imaging modalities such as MRI, PET, and CT scans to visualize structural, functional, and metabolic changes in the brain. Metabolomics biomarkers focus on metabolite profiles and metabolic pathways, providing information on cellular processes and metabolic dysregulation in neurological disorders. The integration of multiple biomarker types enables a comprehensive understanding of disease pathophysiology, aiding in early diagnosis, disease monitoring, and therapeutic development.
The evolution of biomarker technologies and analytical techniques continues to drive innovation and advancements in the Global Neurological Biomarkers Market. Collaborative research efforts, data integration strategies, and technological breakthroughs facilitate the discovery of novel biomarkers and their translation into clinical practice. Biomarker-based approaches hold promise for improving diagnostic accuracy, patient stratification, and treatment outcomes in neurological disorders, ushering in a new era of precision neurology.
Global Neurological Biomarkers Market, Segmentation by Indication
The Global Neurological Biomarkers Market has been segmented by Indication into Spinal Muscular Atrophy, Parkinson’s Disease, Schizophrenia, Huntington’s Disease, Alzheimer’s Disease, Depression, and Multiple Sclerosis.
The segmentation of the Global Neurological Biomarkers Market by indication reflects the diverse range of neurological disorders that biomarkers are utilized to diagnose, monitor, and manage. Spinal Muscular Atrophy (SMA) represents a critical segment, with biomarkers playing a crucial role in early detection and disease progression monitoring. Biomarkers in SMA focus on assessing motor neuron function, muscle integrity, and genetic markers, aiding in personalized treatment approaches and therapeutic development.
Parkinson's Disease, characterized by motor impairments and neurodegeneration, is another significant segment in the Global Neurological Biomarkers Market. Biomarkers for Parkinson's encompass a wide range of indicators, including alpha-synuclein levels, dopamine metabolites, and neuroimaging markers. These biomarkers aid in early diagnosis, disease staging, and tracking treatment responses, facilitating precision medicine interventions and disease management strategies.
Schizophrenia, Huntington's Disease, Alzheimer's Disease, Depression, and Multiple Sclerosis are also key segments within the Global Neurological Biomarkers Market. Biomarkers in these indications vary widely, covering aspects such as neurotransmitter levels, neuroinflammatory markers, genetic variants, and neuroimaging findings. The use of biomarkers in these disorders contributes to improved diagnostic accuracy, patient stratification for clinical trials, and monitoring treatment efficacy, ultimately enhancing patient care and outcomes.
The integration of biomarkers into clinical practice across these neurological indications signifies a paradigm shift towards personalized and precision medicine. Biomarker-based approaches enable targeted interventions, early intervention strategies, and disease-modifying therapies, fostering advancements in neurological care. Collaborative efforts among researchers, healthcare providers, and industry stakeholders drive the development and validation of biomarkers, paving the way for improved diagnostics, prognostics, and therapeutics in neurological disorders.
Global Neurological Biomarkers Market, Segmentation by Imaging Techniques
The Global Neurological Biomarkers Market has been segmented by Imaging Techniques into Transcranial Magnetic Stimulation, Diffusion Tensor Imaging, Conventional Structural MRI, Functional Magnetic Resonance Imaging, and Positron Emission Tomography.
The segmentation of the Global Neurological Biomarkers Market by imaging techniques reflects the diverse approaches used in neurological research and diagnosis. Transcranial Magnetic Stimulation (TMS) stands out as a non-invasive technique that modulates neuronal activity, offering insights into brain function and connectivity. TMS is utilized in studying neurological disorders such as depression, stroke recovery, and motor disorders, making it a valuable tool for biomarker identification and therapeutic assessment.
Diffusion Tensor Imaging (DTI) is another crucial imaging technique in neurology, enabling the visualization of white matter tracts and assessing microstructural changes in brain tissues. DTI's ability to detect abnormalities associated with neurodegenerative diseases, traumatic brain injuries, and developmental disorders enhances its utility in biomarker discovery and disease monitoring. The detailed structural information provided by DTI contributes significantly to understanding brain connectivity and pathology.
Conventional Structural MRI, Functional Magnetic Resonance Imaging (fMRI), and Positron Emission Tomography (PET) are also integral segments of the Global Neurological Biomarkers Market. Structural MRI offers high-resolution images for anatomical assessments, aiding in identifying structural abnormalities and lesions indicative of neurological conditions. fMRI, on the other hand, measures brain activity by detecting changes in blood flow, facilitating the study of cognitive functions, neural networks, and response to stimuli. PET imaging utilizes radioactive tracers to visualize metabolic processes and molecular changes, providing valuable information on neurochemical alterations associated with neurological disorders. The combination of these imaging modalities enables a comprehensive approach to biomarker identification, disease characterization, and treatment evaluation in neurology.
These diverse imaging techniques contribute synergistically to advancing neurological biomarker research, enabling clinicians and researchers to explore brain structure, function, and connectivity with unprecedented detail. The integration of advanced imaging technologies with biomarker analysis holds promise for improving early diagnosis, personalized treatment strategies, and better patient outcomes in neurological care.
Global Neurological Biomarkers Market, Segmentation by End User
The Global Neurological Biomarkers Market has been segmented by End User into Clinical Diagnostics, Pharmaceutical And Biotechnology Companies, Research Organizations and Surgical Center.
The global neurological biomarkers market is segmented by end-user into several key categories, each playing a crucial role in the market's growth and application. Clinical diagnostics is one of the largest segments, as neurological biomarkers are essential in diagnosing various neurological diseases, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. These biomarkers aid clinicians in identifying early-stage diseases, monitoring disease progression, and assessing treatment responses. As the demand for early and accurate diagnostic tools increases, the clinical diagnostics segment is expected to continue expanding, driven by advancements in biomarker discovery and diagnostic technology.
Pharmaceutical and biotechnology companies form another significant segment of the neurological biomarkers market. These companies utilize biomarkers for drug discovery and development, particularly in the context of neurological disorders. Biomarkers help in identifying potential therapeutic targets, predicting patient responses to drugs, and monitoring treatment efficacy during clinical trials. With the rising number of neurological disorders and the growing need for targeted therapies, pharmaceutical and biotech companies are increasingly investing in neurological biomarker research to develop personalized medicine and innovative treatments, driving the market's demand within this segment.
Research organizations and surgical centers also represent important end users in the neurological biomarkers market. Research organizations use biomarkers to explore the underlying causes of neurological diseases and to facilitate the development of new diagnostic tools and therapies. Additionally, surgical centers rely on biomarkers to assist in pre-surgical planning, particularly for conditions requiring neurosurgery, by providing insights into disease progression and surgical risks. As the understanding of neurological diseases deepens, the role of research institutions and surgical centers in advancing the use of biomarkers in clinical applications is expected to grow, further enhancing the market's expansion across these sectors.
Global Neurological Biomarkers Market, Segmentation by Geography
In this report, the Global Neurological Biomarkers Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Neurological Biomarkers Market Share (%), by Geographical Region, 2024
The Global Neurological Biomarkers Market exhibits a dynamic distribution across different geographical regions, with each region contributing uniquely to the market landscape. North America holds a substantial share, accounting for approximately X% of the market. This dominance is attributed to advanced healthcare infrastructure, significant investments in research and development, and a high prevalence of neurological disorders. Moreover, the presence of key market players and favorable regulatory frameworks further strengthens North America's position in the global market. The region's focus on personalized medicine and innovative diagnostic technologies continues to drive market growth and technological advancements in biomarker research.
Europe follows closely behind, comprising around X% of the Global Neurological Biomarkers Market share. The region's robust healthcare systems, emphasis on precision medicine, and supportive reimbursement policies contribute to its market prominence. Collaborative research initiatives and strategic partnerships between academic institutions, biotechnology companies, and healthcare providers propel innovation in biomarker discovery and validation. Europe's proactive approach to addressing neurological disorders and advancing biomarker-based diagnostics and therapies ensures sustained market expansion and improved patient outcomes.
Asia Pacific emerges as a rapidly growing region in the Global Neurological Biomarkers Market, accounting for approximately X% of the market share. Factors such as increasing healthcare expenditure, rising awareness about neurological disorders, and expanding biotechnology sectors drive market growth in this region. Moreover, initiatives aimed at enhancing healthcare infrastructure, adoption of digital health technologies, and growing investments in research and development fuel the demand for neurological biomarkers. Collaborative efforts among industry players, government bodies, and research institutions stimulate market growth and create opportunities for market penetration and product innovation in Asia Pacific.
Neurological Biomarkers Market Forces
This report provides an in depth analysis of various factors that impact the dynamics of Neurological Biomarkers Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces Drivers, Restraints, and Opportunities affect key business dimensions including Growth, Competition, Customer Behavior, Regulation and Innovation.
| Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
|---|---|---|---|---|---|
| Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
| Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
| Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers
- Technological advancements
- Increasing prevalence
- Growing geriatric population
- Rising awareness
-
Demand for personalized medicine : The demand for personalized medicine is a significant driver for the Neurological Biomarkers Market. As healthcare shifts towards individualized treatment plans, biomarkers play a crucial role in identifying patient-specific responses to therapies. Biomarkers offer insights into disease progression, treatment efficacy, and potential adverse effects, enabling healthcare providers to tailor interventions for better outcomes.
Advancements in molecular biology and genetic profiling have expanded the scope of biomarker research. The ability to identify specific biomarkers associated with neurological disorders has opened new avenues for targeted therapies and early disease detection. Integrating biomarker data with other health information allows for a comprehensive approach to patient care, driving further innovation in the field.
The rising prevalence of neurological disorders such as Alzheimer's, Parkinson's, and multiple sclerosis has intensified the focus on biomarker research. The need for reliable diagnostic tools and prognostic indicators fuels investments in biomarker development, creating a conducive environment for market growth.
Restraints
- High cost involved
- Regulatory hurdles
- Lack of skilled professionals
- Limited reimbursement policies
-
Ethical concerns : Ethical concerns pose a significant restraint to the Neurological Biomarkers Market. The use of biomarkers raises questions regarding patient privacy, consent, and data security. Ethical guidelines and regulatory frameworks must evolve to address these concerns and ensure responsible biomarker utilization in clinical settings.
The interpretation and validation of biomarker data present challenges. Variability in biomarker expression, sample collection methods, and data analysis techniques can lead to inconsistent results and hinder the adoption of biomarker-based diagnostics and treatments. Overcoming these technical and scientific barriers is essential for the market's sustainable growth.
Limited reimbursement policies for biomarker testing and interpretation limit access to these innovative technologies, especially in resource-constrained settings. Addressing reimbursement challenges and advocating for the value of biomarkers in improving patient outcomes are crucial steps in overcoming this restraint.
Opportunities
- Emerging markets expansion
- Collaborative research initiatives
- Development of novel biomarkers
- Integration of AI
-
Telemedicine advancements : The integration of AI presents a significant opportunity for the Neurological Biomarkers Market. AI algorithms can analyze complex biomarker data, identify patterns, and generate actionable insights for healthcare providers. Machine learning techniques enhance diagnostic accuracy, predict treatment responses, and facilitate personalized medicine approaches, driving the market forward.
Advancements in telemedicine and remote patient monitoring create new avenues for biomarker utilization. Remote biomarker testing, coupled with teleconsultations, improves patient access to specialized care, particularly in underserved regions. This convergence of healthcare technologies enhances patient outcomes and expands the market's reach.
Collaborative research initiatives among academia, industry, and healthcare organizations foster innovation in biomarker discovery and validation. Public-private partnerships, data sharing agreements, and joint investment efforts accelerate biomarker development, leading to a diversified portfolio of diagnostic tools and therapeutic targets.
Neurological Biomarkers Market Competitive Landscape Analysis
Neurological Biomarkers Market is experiencing steady growth with increasing reliance on advanced diagnostic tools to support precision medicine. Key players are focusing on collaboration, merger, and partnerships to strengthen their portfolios and enhance clinical adoption. Rising demand for early detection is reshaping competitive strategies as companies invest in technological solutions for long-term expansion.
Market Structure and Concentration
The market exhibits a moderately concentrated profile where a few major players hold significant shares, accounting for nearly 45% of total activity. Strong strategies around acquisitions and merger deals are consolidating influence, while mid-tier companies are leveraging collaboration with research institutions to expand clinical validation and boost credibility in neurological testing protocols.
Brand and Channel Strategies
Leading companies are emphasizing brand trust through consistent quality, diversified channels, and specialized neurological testing platforms. Partnerships with hospitals and research networks remain central to distribution strategies. Increasing reliance on digital platforms ensures broader reach, while brand positioning is reinforced by investments in training and support to accelerate growth in clinical adoption rates.
Innovation Drivers and Technological Advancements
Rapid technological advancements are fueling innovation across biomarker discovery, assay design, and AI-driven analytics. Over 35% of new launches highlight integration of machine learning to improve predictive accuracy. Ongoing collaboration with academic laboratories is fostering breakthroughs in biomarker panels, enabling companies to sustain growth while maintaining differentiation in this evolving diagnostic landscape.
Regional Momentum and Expansion
Regional markets are witnessing rising adoption, with North America holding more than 40% share due to strong research funding and institutional partnerships. Europe emphasizes clinical trial collaboration, while Asia-Pacific leads in market expansion supported by increasing healthcare investments. Localized strategies and government initiatives are boosting penetration, strengthening the long-term relevance of neurological biomarker solutions.
Future Outlook
The sector’s future outlook is defined by sustained growth, heightened innovation, and continued collaboration among pharmaceutical firms, diagnostic developers, and research centers. Strategic partnerships and cross-industry initiatives will accelerate biomarker validation, shaping regulatory acceptance. With strong momentum in R&D and targeted expansion, the neurological biomarkers market is set to advance as a critical component of modern healthcare.
Key players in Neurological Biomarkers Market include:
- Abbott
- Thermo Fisher Scientific
- Merck KGaA
- Bio-Rad Laboratories
- Johnson & Johnson Services, Inc.
- Banyan Biomarkers, Inc.
- DiaGenic ASA
- Quanterix
- Fujirebio
- BioMérieux
- Siemens Healthineers
- Roche (F. Hoffmann-La Roche)
- ADx NeuroSciences NV
- Olink Biosciences
- Qiagen
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Market Share Analysis
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Application
- Market Snapshot, By End Use
- Market Snapshot, By Region
- Neurological Biomarkers Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Technological advancements
- Increasing prevalence
- Growing geriatric population
- Rising awareness
- Demand for personalized medicine
- Restraints
- High cost involved
- Regulatory hurdles
- Lack of skilled professionals
- Limited reimbursement policies
- Ethical concerns
- Opportunities
- Emerging markets expansion
- Collaborative research initiatives
- Development of novel biomarkers
- Integration of AI
- Telemedicine advancements
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Neurological Biomarkers Market, By Type, 2021 - 2031 (USD Million)
- Genomic
- Proteomic
- Metabolomic
- Imaging
- Others
- Neurological Biomarkers Market, By Application, 2021 - 2031 (USD Million)
- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Autism Spectrum Disorder
- Others
- Neurological Biomarkers Market, By End Use, 2021 - 2031 (USD Million)
- Research Organizations
- Pharma & Biotech Companies
- Clinical Diagnostics
- Neurological Biomarkers Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Neurological Biomarkers Market, By Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Abbott
- Thermo Fisher Scientific
- Merck KGaA
- Bio-Rad Laboratories
- Johnson & Johnson Services, Inc.
- Banyan Biomarkers, Inc.
- DiaGenic ASA
- Quanterix
- Fujirebio
- BioMérieux
- Siemens Healthineers
- Roche (F. Hoffmann-La Roche)
- ADx NeuroSciences NV
- Olink Biosciences
- Qiagen
- Company Profiles
- Analyst Views
- Future Outlook of the Market